Leuprolide Acetate Suspension

The core mechanism of it in treating central precocious puberty relies on the synergistic advantages of its high-potency LH-RH derivative properties and the suspension formulation, enabling bidirectional regulation and long-acting inhibition of the HPG axis. As a synthetic gonadotropin-releasing hormone (GnRH) agonist, its active ingredient has a far higher affinity for pituitary GnRH receptors than endogenous GnRH and exhibits stronger resistance to proteolytic enzymes. The suspension formulation, through microparticle dispersion technology, uniformly suspends the drug in a solvent; after injection, it slowly dissolves and releases the drug in subcutaneous or muscular tissue, preventing abrupt rises and falls in blood drug concentration.

A transient "flare reaction" occurs at the initial stage of administration, which briefly stimulates the pituitary gland to secrete luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to a temporary increase in sex hormone levels. This may cause a slight exacerbation of secondary sexual characteristics in some pediatric patients, but the reaction is short-lived and resolves spontaneously with continued medication. With sustained administration, the sustained-release property of the suspension formulation maintains a stable blood drug concentration, and inhibits the sensitivity of pituitary GnRH receptors through negative feedback regulation. This reduces the secretion of LH and FSH to pre-pubertal levels significantly, thereby inhibiting the response of the ovaries or testes to gonadotropins, lowering estradiol and testosterone concentrations, blocking the progression of secondary sexual characteristics, and slowing down the rate of bone age closure to gain time for height growth.

Clinical studies have confirmed that Leuprorelin Acetate Suspension has definitive efficacy in the treatment of central precocious puberty, achieving the multiple goals of secondary sexual characteristic control, bone age delay and height preservation, with its efficacy unaffected by the patient's body mass index (BMI). In terms of secondary sexual characteristic control, the progression of secondary sexual characteristics slows significantly in most pediatric patients after 1-2 treatment cycles: breast development stagnates and vaginal bleeding ceases in girls, while testicular enlargement and pubic hair growth are inhibited in boys. After 1 year of treatment, the volume of the ovaries and uterus, as well as follicle diameter, are significantly reduced in girls, and sex hormone levels stabilize at pre-pubertal ranges.

In terms of height preservation, the long-acting inhibitory effect of the suspension formulation effectively delays bone age closure, gaining valuable time for height growth. A South Korean cohort study showed that girls who started treatment before the age of 8 had a predicted height gain of 1.5 centimeters after 1 year of medication, with a significant decrease in the rate of bone age progression. Menarche resumed naturally in patients 0.9-1.5 years after drug withdrawal, with a mean age of resumption of 12.6-13.6 years, consistent with the normal pattern of pubertal development. In addition, serum bone metabolism markers (amino-terminal propeptide of type I procollagen, β-crosslaps, etc.) are significantly reduced after treatment, slowing the rate of bone metabolism, which further confirms its inhibitory effect on bone age progression and provides a guarantee for the improvement of final adult height.

The synthesis of Leuprorelin Acetate Suspension active pharmaceutical ingredient (API) is predominantly based on the solid-phase synthesis method, with the core being the stepwise coupling of amino acids to construct a nonapeptide structure. Precise control is implemented throughout the entire process to ensure high purity and biological activity. The Fmoc or Boc protection strategy is adopted, with polystyrene resin as the solid-phase carrier, and amino acids are coupled sequentially starting from the C-terminus. After each coupling step, reaction efficiency is verified through professional testing to strictly prevent the formation of by-products such as deletion peptides. The crude peptide undergoes multi-stage purification via reversed-phase high-performance liquid chromatography (RP-HPLC) to completely remove impurities and residual reactants, followed by salt conversion via ion exchange to form the acetate salt.

The long-acting sustained-release property of the suspension relies on the precise preparation of PLGA microspheres and construction of the suspension system, with the core being the implementation of drug loading via the emulsification-solvent evaporation method.The product, PLGA, gelatin and other raw materials are dissolved in dichloromethane to form an organic phase, which is then added to an aqueous phase containing a surfactant. High-speed emulsification is performed to form an O/W emulsion, and PLGA is solidified to form microspheres through slow solvent evaporation. The particle size of the microspheres is strictly controlled within the range of 1-10 μm, which ensures suspension uniformity and achieves stable drug release simultaneously. After washing and freeze-drying, the microspheres are mixed with mannitol to form the powder in the front chamber of a dual-chamber syringe; the diluent in the rear chamber is prepared by carefully proportioning sodium carboxymethylcellulose, polysorbate 80, acetic acid and other components, and the pH of the system is adjusted to 4.0-6.0.

A full-process quality control system must be established during the manufacturing process, with multi-dimensional testing conducted from raw materials to finished products to ensure the safety, efficacy and stability of the product. In the API stage, the key monitoring indicators are purity and acetate ion content: the purity must be no less than 99%, and the acetate ion content must comply with established standards to ensure a stable foundation for drug efficacy. In the microsphere preparation stage, the core control indicators are particle size distribution and drug loading: the particle size must be strictly maintained at 1-10 μm, and the drug loading deviation must be controlled within ±5%, which directly determines the subsequent drug release rate. For the finished Leuprorelin Acetate Suspension, pH value and microparticle stability are tested: the pH value must be stable at 4.0-6.0, and no obvious sedimentation occurs within 30 minutes after reconstitution, ensuring uniform drug distribution after administration.

Packaging and storage conditions directly affect the shelf life and usage safety of the product, and strict compliance with professional specifications is required. The product is packaged in dual-chamber pre-filled syringes made of light-proof materials, which effectively block the oxidative damage to the drug caused by light; the sealing system adopts high-barrier materials to prevent the infiltration of air and moisture, avoiding moisture absorption and caking of microspheres. Meanwhile, a special diluent is provided to ensure immediate injection after mixing. Storage must be in a light-proof environment below 25℃, and freezing storage is strictly prohibited, as freezing will damage the microsphere structure and cause loss of sustained-release function; violent shaking must be avoided during transportation to prevent changes in microsphere particle size that may affect drug efficacy.